The Clinical Times
The Front Page of Medicine

Latest medical news · page 143

The latest headlines across every section, pulled from official and open-access sources.

ACC (Cardiology) · Jun 25, 2026

HHS Releases Consumer Alert on Fraudulent CV Testing Schemes

The U.S. Department of Health and Human Services' (HHS') Office of Inspector General has issued a consumer alert, urging parents, caregivers, athletic programs and student athletes to beware of fraudulent cardiovascular testing schemes exploiting fears around sudden cardiac arrest in young athletes.

ADA (Diabetes) · Jun 25, 2026

The American Diabetes Association Expresses Concern Over Rhode Island’s Decision to Eliminate Medicaid Coverage of Obesity Treatments

The American Diabetes Association Expresses Concern Over Rhode Island’s Decision to Eliminate Medicaid Coverage of Obesity Treatments mcarmody Thu, 06/25/2026 - 19:39 Advocacy News The American Diabetes Association Expresses Concern Over Rhode Island’s Decision to Eliminate Medicaid Coverage of Obesity Treatments ARLINGTON, Va. June 25, 2026 The Rhode Island General Assembly’s Fiscal Year 2027 (FY 2027) budget adopted a policy change that limits Medicaid coverage of glucagon-like peptide-1 (GLP-1)-based medications to only individuals with type 2 diabetes.  Beginning October 1, 2026…

ACC (Cardiology) · Jun 25, 2026

Combined LDL-C, Lp(a) and hsCRP Assessment Identifies Long-Term Risk of ASCVD

Combined assessment of LDL-C, Lp(a) and hsCRP reflected independent pathways for identifying individuals of varied ethnicities at greater long-term risk of atherosclerotic cardiovascular disease (ASCVD), according to an analysis of the HELIUS cohort published June 24 in JACC.

FDA Drugs · Jun 25, 2026

Report on the State of Pharmaceutical Quality

The mission of the Office of Pharmaceutical Quality is to assure that quality medicines are available to the American public. The annual Report on the State of Pharmaceutical Quality is intended to help characterize the quality of the U.S. drug supply chain. Learn more.

ACC (Cardiology) · Jun 25, 2026

2026 Mid-Year Update on ACC Advocacy Efforts

Throughout the first half of 2026, ACC’s Advocacy Team has been actively engaged in shaping policy at both the federal and state levels and working with policymakers to support cardiovascular clinicians and improve patient care nationwide. Read about key highlights from this work below.

ACC (Cardiology) · Jun 25, 2026

New Risk Score Helps Identify Bleeding Risk With DOACs in Cancer-Associated VTE

The novel ONCO-DOAC BLEED risk score, developed by Tomoyuki Nagai, MD, et al., provided clinically relevant major bleeding risk stratification for patients with cancer-associated venous thromboembolism (VTE) receiving direct oral anticoagulants (DOAC), according to research published June 16 in JACC: CardioOncology.

MedTech Dive · Jun 25, 2026

BD’s Bilal Muhsin talks AI in connected care

Muhsin discussed how BD is rolling out a new medication dispenser and a software platform that pulls together data from the company’s various devices.

ACC (Cardiology) · Jun 25, 2026

Clopidogrel May Offer Long-Term Edge Over Aspirin After PCI

Clopidogrel monotherapy was associated with lower risks of major adverse cardiovascular events (MACE) and major bleeding compared with aspirin monotherapy among stable patients post PCI, according to a nationwide cohort study published June 15 in JACC: Asia.

ACC (Cardiology) · Jun 25, 2026

Long-Term Exposure to PM2.5 Components Increases CVD Risk

Long-term exposure to specific chemical components of fine particulate matter with diameters ≤2.5 μm (PM2.5) was associated with an increased risk of developing cardiovascular disease, according to a large cohort study published June 24 in JACC.

ACC (Cardiology) · Jun 25, 2026

PARTNER 2A, P2S3i Registry: 10-Year TAVR Outcomes With SAPIEN XT, SAPIEN 3

The rates of mortality and reintervention at 10 years were higher in patients at intermediate risk who underwent TAVR with the second-generation SAPIEN XT valve than those who underwent surgery in the PARTNER 2A trial, according to an analysis published June 16 in a valvular heart disease focus issue of JACC.

BMJ Open · Jun 25, 2026

Strategic analysis of electronic prescriptions in Iran: a qualitative study

Objectives This study aims to examine the electronic prescription programme in Iran by thoroughly identifying the key strengths, weaknesses, opportunities and threats (SWOT) associated with its implementation and utilisation among healthcare stakeholders. Design A thematic analysis was adopted, with data systematically examined through the SWOT analytical framework. Setting Hospital, pharmacy, specialised clinic, insurance affiliated clinic in Iran. Participants Participants consisted of four groups involved in implementing the electronic prescription programme, including physicians…

← NewerOlder →

Back to the live front page